Chad Robins

Chad Robins is the co-founder and CEO of Adaptive Biotechnologies (NASDAQ: ADPT), a commercial-stage biotech company with an innovative platform that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Prior to co-founding Adaptive, Chad held numerous executive-level positions in medical technology, investment and real estate companies. In addition to AltPep, Chad is on the boards of Headlight, Life Science Washington, and AdvaMedDx. Chad holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Managerial Economics from Cornell University.